Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis.
Vianna
Raul N G
RN
Squeri
Giuseppe
G
Turquetti
Remo
R
Brasil
O F M
OF
Burnier
M N
MN
D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D002199:Capillary Permeability; D005260:Female; D019793:Fluorescein / Q000378:metabolism*; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D007267:Injections; D008875:Middle Aged; D012164:Retinal Diseases / Q000188:drug therapy* / Q000378:metabolism; D012171:Retinal Vessels / Q000187:drug effects* / Q000378:metabolism; D013684:Telangiectasis / Q000188:drug therapy* / Q000378:metabolism; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D019793:Fluorescein